Antoine Angelergues1, Eleni Efstathiou2, Revekka Gyftaki2, Piotr Jan Wysocki3, Nuria Lainez4, Iria Gonzalez5, Daniel E Castellano6, Mustafa Ozguroglu7, Iciar Garcia Carbonero8, Aude Flechon9, Pablo Borrega10, Aline Guillot11, Begona Campos Balea12, Sylvestre Le Moulec13, Emilio Esteban14, Javier Munarriz15, Gustavo Rubio16, Alison J Birtle17, Nicolas Delanoy1, Joaquim Bellmunt18, Stéphane Oudard19. 1. Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France. 2. Alexandra General Hospital of Athens, University of Athens, Athens, Greece. 3. M. Sklodowska-Curie Memorial Cancer Center Institute, Warsaw, Poland. 4. Complejo Hospitalario de Navarra, Pamplona, Spain. 5. University Hospital del Mar-IMIM, Barcelona, Spain. 6. Hospital Universitario 12 de Octubre, Madrid, Spain. 7. Istanbul University, Istanbul, Turkey. 8. Medical Oncology Department, Hospital Virgen de la Salud, Toledo, Spain. 9. Centre Léon Bérard, Lyon, France. 10. Hospital San Pedro de Alcántara, Cáceres, Spain. 11. Institut de Cancérologie de la Loire, Saint-Etienne, France. 12. Hospital Universitario Lucus Augusti, Lugo, Spain. 13. Val-de-Grâce Hospital, Paris, France. 14. Hospital Universitario Central de Asturias, Oviedo, Spain. 15. Hospital Provincial de Castellón, Castellón, Spain. 16. Oncology Department, Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain. 17. Rosemere Cancer Centre, Royal Preston Hospital, Preston, United Kingdom. 18. University Hospital del Mar-IMIM, Barcelona, Spain. Electronic address: jbellmunt@imim.es. 19. Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France; Université Paris Descartes Sorbonne Paris-Cité, Paris, France. Electronic address: stephane.oudard@aphp.fr.
Abstract
BACKGROUND: Several agents have demonstrated an overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC); however, the optimal sequencing of these therapies is unknown as a result of a lack of prospective randomized controlled trials. This retrospective study aimed to identify clinical factors influencing outcomes and to determine optimal treatment sequencing in patients with mCRPC treated with cabazitaxel (CABA) and/or androgen receptor-targeted agents (ART) after androgen-deprivation therapy (ADT) and docetaxel (DOC). PATIENTS AND METHODS: Records of 574 consecutive patients treated (2012-2016) at 44 centers in 6 countries were retrospectively examined. RESULTS: A total of 267 patients received ADT → DOC → CABA (group 1), 183 patients ADT → DOC → ART → CABA (group 2), and 124 patients ADT → DOC → CABA → ART (group 3), with respective median OS from diagnosis of mCRPC of 38.3, 44.45, and 53.9 months (P = .012 for group 3 vs. group 1). Multivariate analysis showed response to first ADT ≤ 12 months, Gleason score of 8 to 10, clinical progression, and high prostate-specific antigen levels at mCRPC diagnosis were associated with worse OS. Prior receipt of ART did not influence activity of CABA. CONCLUSION: OS appeared to increase with the number of life-extending therapies, with a sequence including DOC, CABA, and an ART providing the greatest OS benefit.
BACKGROUND: Several agents have demonstrated an overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC); however, the optimal sequencing of these therapies is unknown as a result of a lack of prospective randomized controlled trials. This retrospective study aimed to identify clinical factors influencing outcomes and to determine optimal treatment sequencing in patients with mCRPC treated with cabazitaxel (CABA) and/or androgen receptor-targeted agents (ART) after androgen-deprivation therapy (ADT) and docetaxel (DOC). PATIENTS AND METHODS: Records of 574 consecutive patients treated (2012-2016) at 44 centers in 6 countries were retrospectively examined. RESULTS: A total of 267 patients received ADT → DOC → CABA (group 1), 183 patientsADT → DOC → ART → CABA (group 2), and 124 patientsADT → DOC → CABA → ART (group 3), with respective median OS from diagnosis of mCRPC of 38.3, 44.45, and 53.9 months (P = .012 for group 3 vs. group 1). Multivariate analysis showed response to first ADT ≤ 12 months, Gleason score of 8 to 10, clinical progression, and high prostate-specific antigen levels at mCRPC diagnosis were associated with worse OS. Prior receipt of ART did not influence activity of CABA. CONCLUSION: OS appeared to increase with the number of life-extending therapies, with a sequence including DOC, CABA, and an ART providing the greatest OS benefit.
Authors: P Albers; M Bögemann; S Machtens; A S Merseburger; M Schostak; T Steuber; C Wülfing; M De Santis Journal: Urologe A Date: 2020-03 Impact factor: 0.639
Authors: Neal D Shore; François Laliberté; Raluca Ionescu-Ittu; Lingfeng Yang; Malena Mahendran; Dominique Lejeune; Louise H Yu; Joseph Burgents; Mei Sheng Duh; Sameer R Ghate Journal: Adv Ther Date: 2021-07-19 Impact factor: 3.845